Superworth

Sight Sciences price to sales ratio SGHT

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026
5.9×
5-year median
3.8×
Against its 5-year history
77th
percentile: 0 is its lowest day, 100 its highest
5-year range
0.9× to 13.1×
Peer median
2.0×

Sight Sciences' price to sales ratio is 5.9× as of Oct 23, 2026.

That is above its 5-year median of 3.8×, higher than on 77% of days in the last 5 years.

Over that time it ranged from 0.9× in Oct 2023 to 13.1× in Mar 2022.

The median for 10 medical instruments and supplies stocks of a similar size is 2.0×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.9×2.4×5.9×
20256.1×1.5×6.1×
20242.3×2.3×4.7×
20233.0×0.9×9.8×
20229.0×4.9×13.1×

Against its peers

Companies in Medical - Instruments & Supplies nearest Sight Sciences' size, closest first, today.

CompanyPrice to sales ratio
SGHTSight Sciences5.9×
TCMDTactile Systems Technology1.5×
MDXGMimedx1.6×
EMBCEmbecta0.4×
MOVMovado1.0×
INFUInfuSystem1.9×
UTMDUtah Medical Products6.5×
IRMDIradimed12.7×
STAAStaar Surgical3.3×
PDEXPro DEX2.6×
BVSBioventus2.2×
Peer median2.0×

Where Sight Sciences ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Sight Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.